Follow us on Twitter
twitter icon@FreshPatents


Diabetes patents

      

This page is updated frequently with new Diabetes-related patent applications.

SALE: 520+ Diabetes-related patent PDFs



 Proteins increasing pancreatic beta cell number and methods of use patent thumbnailProteins increasing pancreatic beta cell number and methods of use
Disclosed herein are bacterial proteins that increase pancreatic beta (β) cell number and/or proliferation, methods of increasing β cell number and/or proliferation using such proteins, and methods of treating or inhibiting diabetes in a subject by administering such proteins to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as any one of seq id nos: 1-7, or fragments thereof.
University Of Oregon


 Growth differentiation factor 15 (gdf-15) polypeptides patent thumbnailGrowth differentiation factor 15 (gdf-15) polypeptides
Gdf15 polypeptides, constructs comprising gdf15, and mutants thereof are provided. In various embodiments the gdf15 polypeptides, constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder.
Amgen Inc.


 Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes patent thumbnailSubstituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
Wherein u1, u2, u3, r1, r2, z, and w are defined herein.. .

 Adeno-associated viral vectors for the gene therapy of metabolic diseases patent thumbnailAdeno-associated viral vectors for the gene therapy of metabolic diseases
The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors.
Universitat Autonoma De Barcelona


 Oral spray containing ixeris dentata nakai extract as active ingredient for preventing or treating xerostomia caused by diabetes patent thumbnailOral spray containing ixeris dentata nakai extract as active ingredient for preventing or treating xerostomia caused by diabetes
When the ixeris dentata nakai extract is administered using the formulation of the present invention, the ixeris dentata nakai extract is sublingually sprayed through the spray formulation, and thus can be directly locally administered to a salivary gland tissue having an activity to induce secretion of saliva. Therefore, saliva secretion can be induced by rapid absorption of the active ingredient of the ixeris dentata nakai extract in the salivary gland tissue without any absorption process through the digestive system, resulting in minimized side effects..

 Method and composition for treatment or prevention of type 2 diabetes and hyperlipidemia patent thumbnailMethod and composition for treatment or prevention of type 2 diabetes and hyperlipidemia
The present invention provides a method of treating or preventing type 2 diabetes and hyperlipidemia in a subject in need thereof, comprising administrating to the subject a therapeutically effective amount of a compound of formula i. The present invention also provides a pharmaceutical composition for treatment or prevention of type 2 diabetes and hyperlipidemia, comprising a compound of formula i and a pharmaceutically acceptable carrier.

 Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm patent thumbnailTreatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low dhea or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (dhea) and a selective estrogen receptor modulator (serm) (particularly acolbifene), an antiestrogen or a prodrug of the two. The symptoms or diseases are loss of libido, erectile dysfunction, tiredness, loss of energy, depression, bone loss, muscle loss, muscle weakness, fat accumulation, memory loss, cognition loss, alzheimer's disease, dementia, loss of body hair, fertility problems, insomnia, gynecomastia, anemia, hot flushes, sweats, decreased sense of well-being, obesity, osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, cardiovascular disease and type 2 diabetes.
Endorecherche, Inc.


 Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions patent thumbnailMethod of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions
The present invention relates to a polyphenol derivative of the stilbenoid family, namely trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, as a remedial agent. In particular, the present invention presents the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (pscs).
Hong Kong Baptist University


 Peptides having reduced toxicity that stimulate cholesterol efflux patent thumbnailPeptides having reduced toxicity that stimulate cholesterol efflux
The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., apo ai and apo e), and having high selectivity for abca1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses.
The Regents Of The University Of California


 Compounds and methods for kinase modulation, and indications therefor patent thumbnailCompounds and methods for kinase modulation, and indications therefor
In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of fms, kit, flt3, trka, trkb and trkc kinase protein. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of one or more of fms, kit, flt3, trka, trkb and trkc, including rheumatoid arthritis, osteoarthritis, osteoporosis, peri-prosthetic osteolysis, systemic sclerosis, demyelinating disorders, multiple sclerosis, charcot marie tooth syndrome, amyotrophic lateral sclerosis, alzheimer's disease, parkinson's disease, global ischemia, ulcerative colitis, crohn's disease, immune thrombocytopenic purpura, atherosclerosis, systemic lupus erythematosis, myelopreparation for autologous transplantation, transplant rejection, glomerulonephritis, interstitial nephritis, lupus nephritis, tubular necrosis, diabetic nephropathy, renal hypertrophy, type i diabetes, acute pain, inflammatory pain, neuropathic pain, acute myeloid leukemia, melanoma, multiple myeloma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, ovarian cancer, gliomas, glioblastoma, neurofibromatosis, osteolytic bone metastases, brain metastases, gastrointestinal stromal tumors, and giant cell tumors..

Indole derivatives for the prevention and/or treatment of diabetes and associated metabolic disorders

The invention relates to substituted heterocyclic indole derivatives of formula (i), which act as activators of the amp-activated protein kinase (ampk) and to the use of them for the treatment and prevention of diseases or disorders regulated by ampk. As a result, these compounds can be used for the treatment of inflammatory, autoimmune, cardiovascular, neurological diseases and cancer..
Centro De Investigacion Biomedica En Red (ciber)

Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis

Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (als) by inhibiting igg-mediated activation of voltage-gated calcium channels (vgccs) in cells of the subject, by one or more of removing igg from blood of the subject, blocking igg from activating vgccs in the subject; or blocking vgccs in the subject are described, as are methods for identifying als patients at risk of developing diabetes.. .
Biocrine Ab

Multi-cbv vaccine for preventing or treating type i diabetes

The invention is directed to a vaccine comprising: i) coxsackie b virus cbv1 and cbv2, and ii) at least one coxsackie b virus selected from cbv3, cbv4, cbv5 and cbv6. The cbvs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus.
Vactech Oy

Peptide conjugates of glp-1 receptor agonists and gastrin and their use

The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.. .
Zealand Pharma A/s

Pharmaceutical compositions and methods for the treatment of diabetes

This invention relates to compositions and methods for treating type i diabetes. Compositions of the invention include active compounds such as harmine, indy, or derivatives thereof to induce reproduction of beta cells.
University Of Limerick

Smart logging for management of health-related issues

A system managing health-related issues (e.g., diabetes) includes a measurement device to measure a health characteristic and a processing device communicatively coupled to the measurement device. The processing device receives the measurement from the measurement device.
Ascensia Diabetes Care Holdings Ag

Elisa for vegf

The vascular endothelial growth factor (vegf) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich elisa methods and kits for vegf as an antigen are provided to detect types of vegf levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index..
Genentech, Inc.

Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting nox-1

Methods of preserving and/or protecting pancreatic beta cells by inhibiting nox-1. In a further aspect, nox-1 inhibitors are administered to a subject in order to preserve and/or protect beta cells in the prevention or treatment of diabetes.
Eastern Virginia Medical School

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the gipr polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Amgen Inc.

Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

The present invention relates to a compound represented by formula i: and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2.
Merck Sharp & Dohme Corp.

Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase

Compositions and methods are disclosed that relate to small molecule lipopeptidomimetic inhibitors of mammalian ghrelin o-acyl transferase (goat). Compounds of general formula (i) and substructures thereof, i.e., formulae (ii), (iia), (iia1), (iia2), (iib), (iib1), (iib2), (iic) and (iii), are shown to exhibit potent inhibition of the octanoylation of ghrelin peptide, where the resulting non-octanoylated (des-acyl) form of ghrelin lacks ghsr ligand activity that is associated with weight gain and insulin resistance.
The Regents Of The University Of California

Novel antagonists of the glucagon receptor

The present invention provides for novel compounds of formula (i) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including type i and ii diabetes, insulin resistance and hyperglycemia.
Metabasis Therapeutics, Inc.

Polymeric stabilizing formulations

The present invention provides compositions of a therapeutic agent and a polymeric stabilizing agent for stabilizing the reservoir of an implantable drug delivery system. The present invention also includes an implantable drug delivery system incorporating the composition of the present invention, as well as methods of treating diabetes using the compositions and implantable drug delivery system of the present invention..
Nano Precision Medical, Inc.

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

The present invention relates to a compound represented by formula i:and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2.
Merck Sharp & Dohme Corp.

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula (i) are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2.
Merck Sharp & Dohme Corp.

Use of flavonoids in manufacturing compositions for wound healing

Disclosed is a method for wound healing comprising administering a subject in need thereof a therapeutically effective amount of a flavonoid compound, wherein the compound is preferably nonglycosylated flavone. Specifically, the present invention can be used for treating skin symptoms of a trauma, a burn, a scald and a chronic wound, and can be particularly used for healing a wound of a diabetes patient..
Oneness Biotech Co., Ltd

Thermometer device

A device for measuring the temperature of a lower extremity of a subject in need of such monitoring. The device is especially suited for monitoring the foot temperature of a subject with diabetes or another condition that could lead to lower blood circulation and temperature in the lower extremities of the subject.
Jackson State University

Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

The present invention relates to the compound (2r,2′r)-bis(((((tetrahydro-2h-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid p component (sap) would be beneficial, including amyloidosis, alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.. .
Glaxosmithkline Intellectual Property Development Limited

Negative hydrogen ion intellegrnt filtration system for curing cancer, cardiovascular disease, diabetes, hypertension, nephrotic syndrome, gout, dysautonomia and atopic dermatitis

A negative hydrogen ion intelligent filtration system includes a housing; a filtering mechanism disposed in the housing and comprising a first filter, a second filter connected to the first filter, a third filter connected to second filter, a fourth filter connected to the third filter, a fifth filter connected to the fourth filter, a sixth filter connected to the fifth filter, a seventh filter connected to the sixth filter, an eighth filter connected to the seventh filter, a ninth filter connected to the eighth filter, a tenth filter connected to the ninth filter, a eleventh filter connected to the tenth filter and a twelfth filter connected to the eleventh filter; an inflow port connected to the first filter and extending out of the housing; an outflow port connected to the twelfth filter and extending out of the housing; and a flow rate control mechanism disposed in the housing, located between the first filter and the inflow port and connecting the first filter and the inflow port.. .
Mega Sun Biomedical Corp.

Compositions and methods for producing elevated and sustained ketosis

Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/l), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time.
University Of South Florida

Compositions and methods for diagnosis and treatment of metabolic syndrome

Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided..
United States Of America, As Represented By The Secretary Of The Navy

Diabetes testing kit and methods for its use

Methods and apparatuses for use in screening for and assessing neuropathies, such as severe diabetic neuropathies of the feet, also known as loss of protective sensation (“lops”). The methods and apparatuses described herein employ a kit including one or more of an insert having at least one testing instrument attached thereto, the at least one testing instrument comprising at least a holder and a monofilament; an enclosure including inner compartments for holding and securing the insert; a folder having one or more pockets for securing the insert and one or more of a mirror, a packet and other material, such as instructions.
Medical Monofilament Manufacturing Llc

Process for preparation of a grifola frondosa polysaccharide f2 and its hypoglycemic activity

A grifola frondosa polysaccharide f2 with hypoglycemic activity, process for preparation and use thereof. The process for preparation of grifola frondosa polysaccharide f2 is as follows: the fruit bodies of grifola frondosa were homogenized to a fine powder and extracted with hot water.
Guangdong Yuewei Edible Fungi Technology Co.,ltd.

Stabilized insulinotropic peptides and methods of use

The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides.
Dana-farber Cancer Institute, Inc.

Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same

The present invention relates to treatment of diabetes, toll-like receptor 4 (tlr-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (ply peptide) which is effective in treatment of diabetes.
Kemyth Biotech Co., Ltd.

Fgf-8 for use in treating diseases or disorders of energy homeostasis

The present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis.
Technische Universität München

Amine polymers for use as bile acid sequestrants

The present invention provides crosslinked amine polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritus, irritable bowel syndrome-diarrhea (ibs-d), bile acid malabsorption, and the like..
Relypsa, Inc.

Corticosteroid formulations and methods for the treatment of joint pain in patients with diabetes

This invention relates to the use of corticosteroids in patients with diabetes, including patients with type 2 diabetes, to treat pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis without increasing or otherwise significantly impacting blood glucose concentrations in diabetic patients, and to slow, arrest or reverse structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or periarticular tissues caused by osteoarthritis or rheumatoid arthritis without increasing or otherwise impacting blood glucose concentrations. More specifically, a formulation of triamcinolone acetonide (tca) is administered locally to diabetes patients, including type 2 diabetes patients, as a sustained release dosage form (with or without an immediate release component) that results in efficacy levels accompanied by clinically insignificant or no measurable effect on blood glucose levels..
Flexion Therapeutics, Inc.

Fatty acid cysteamine conjugates and their use as activators of autophagy

The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (ipf), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, leigh syndrome, diabetes mellitus and deafness (dad), leber's hereditary optic neuropathy, neuropathy-ataxia-retinis pigmentosa and ptosis (narp), myoneurogenic gastrointestinal encephalopathy (mng1e), myoclonic epilepsy with ragged red fibers (merrf), or mitochondrial myopathy-encephalomy-opathy-lactic acidosis stroke like symptoms (melas), comprising administering to a patient the fatty acid cysteamine conjugate, (4z, 7z. 10z, 13z, 16z, 19z)—n-(2-mercaptoethyl) docosa-4,7,10,13,16,19-hexaenamide or (5z, 8z, 11z, 14z, 17z)—n-(2-mercaptoethyl) icosa-5,8,11,14,17-pentaenamide..
Catabasis Pharmaceuticals, Inc.

Diabetes control using postprandial feedback

Disclosed is a postprandial glucose-measuring device for preventing the development of or reversing t2d. Included are methods for using the device as well as better use for invasive and noninvasive glucose meters.

Rapid screening and evaluation of diabetes and prediabetes by glycated hemoglobin mass spectrometry

The method describes rapid screening of whole blood samples, pin prick and blood spot cards, subjected to maldi-tof mass spectrometry. The spectra is generated and compared to those from normal healthy controls.
Map Ip Holding Limited

Method for detecting and purifying pancreatic beta cells

The invention is based, in part, on the discovery that a polypeptide, referred to herein as betacam, is selectively expressed on the surface of pancreatic islet cells. Thus, in one aspect, the invention is directed to compositions comprising betacam or that can be used to detect betacam.
The Regent Of The University Of Colorado, A Body Corporate

Method for screening drug-saccharide conjugates

Methods for identifying drug-saccharide conjugates that bind the mannose receptor, c type 1, (mrc1) and may be taken up by cells expressing mrc1, and the use of such drug-saccharide conjugates for treatment of particular diseases are described. In particular, the methods for identifying insulin-saccharide conjugates that bind the mrc1 receptor and may be taken up by cells expressing the mrc1 and use of such conjugates for treatment of diabetes are described..
Merck Sharp & Dohme Corp.

2-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof

2-alkoxy benzene formyl arylamine compounds and their pharmaceutical salts are disclosed. The compounds can act as sphingomyelin synthase (sms) inhibitors to treat diseases caused by abnormal increasing of sphingomyelin (sm).
Fudan University

Probability based controller gain

Methods and systems are disclosed for estimating a glucose level of a person having diabetes and selecting automatically open-loop and closed-loop control for a connected therapy delivery device. The method may comprise analyzing measured glucose results and corresponding impedance values received from a glucose sensor coupled to the person with a probability analysis tool implemented by a microcontroller to determine a total quality score that is based on the minimum constraint of a probability of glucose sensor accuracy determined measured glucose results and a probability of sensing quality determined from the impedance values.
Roche Diabetes Care, Inc.

Compounds against ralstonia pickettii for use in the treatment of insulin resistance, and diagnosis of insulin resistance

Compounds disclosed herein are effective against ralstonia pickettii for treating or preventing insulin resistance, obesity or type ii diabetes of a subject, and include an antibiotic effective against ralstonia pickettii, an immunogenic compound producing a protective immune response, or an antibody which specifically binds to ralstonia pickettii or a fragment thereof. In vitro methods for diagnosis or prediction of insulin resistance, obesity or type ii diabetes include determining the presence of ralstonia pickettii or of an antibody which specifically binds to ralstonia pickettii in a test sample.
Wageningen Universiteit

Extract of toona sinensis from supercritical fluid extraction for treating diabetes and metabolic disease, the preparation method and the use thereof

The toona sinensis extract of the present invention is prepared using supercritical fluid technique, wherein the method includes steps of: (a) drying the leaves of t. Sinensis; (b) pulverizing the leaves as particles; and (c) extracting the particles with supercritical carbon dioxide to obtain the t.
Kaohsiung Medical University

Probiotic bifidobacterium adolescentis strains

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated with human pbmc derived dendritic cells. The strains may have one, two or all three of these capabilities.
Chr. Hansen A/s

Patient diabetes monitoring system with clustering of unsupervised daily cgm profiles (or insulin profiles) and method thereof

A patient diabetes monitoring system with an efficient unsupervised daily monitoring profile clustering algorithm, a method, and a computer product thereof are disclosed. The system may include a physiological data input device or sensor which receives a plurality of physiological measurements to generate a dataset, a memory which stores a clustering algorithm, and a processor.
Roche Diabetes Care, Inc.

Method for screening drug-saccharide conjugates

Methods for identifying drug-saccharide conjugates that bind the mannose receptor, c type 1, (mrc1) and may be taken up by cells expressing mrc1, and the use of such drug-saccharide conjugates for treatment of particular diseases are described. In particular, the methods for identifying insulin-saccharide conjugates that bind the mrc1 receptor and may be taken up by cells expressing the mrc1 and use of such conjugates for treatment of diabetes are described..
Merck Sharp & Dohme Corp.

Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

The present invention relates to compositions and methods utilizing anti-tnf antibodies having a heavy chain (hc) comprising seq id no:36 and a light chain (lc) comprising seq id no:37 for use in the treatment or prevention of type i diabetes (t1d).. .
Janssen Biotech, Inc.

Metformin derivatives

The present invention relates to novel biguanide derivatives including their pharmaceutically acceptable salts. The invention also relates processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating disorders such as diabetes..
Biopharma Works Llc

Novel amino-phenyl-sulfonyl-acetate derivatives and use thereof

The present invention relates to a novel amino-phenyl-sulfonyl-acetate derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating diabetes comprising the same as an active ingredient.. .
Cj Healthcare Corporation

Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies

The present disclosure relates to methods for treating type 1 diabetes (t1d) using a glucagon receptor blocking agent. More specifically, the present disclosure relates to methods for treating t1d using substantially lower doses of insulin supple-mentation, or even in the absence of insulin supplementation, using antigen binding and antagonizing proteins, e.g., fully human antibodies that specifically bind to and antagonize the function of the human glucagon receptor..
Remd Biotherapeutics, Inc

Blood glucose lowering compound

The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound..
Amunix Operating Inc.

Peptide for treatment of type 2 diabetes mellitus and its complications

The invention relates to biotechnology. The exenatide analogue with the formula h-his-gly-glu-gly-thr-phe-thr-ser-as-leu-ser-lys-gln-glu-glu-glu-glu-ala-val-arg-leu-phe-ile-glu-trp-leu-lys-asn-gly-gly-pro-ser-ser-gly-ala- pro-pro-pro-ser-d-arg-d-arg-d-arg-d-arg-d-arg-d-arg-d-arg-d-arg-gly-oh is presented.
Daphot Enterprises Limited

Modulating gamma-c-cytokine activity

Peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Compositions and methods for regulating glucose homeostasis and insulin action

The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to bam15 ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia.
University Of Virginia Patent Foundation

Soluble epoxide hydrolase inhibitors and uses thereof

The present invention features compounds having soluble epoxide hydrolase inhibitory activity. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions, such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes..
X-chem, Inc.

Composition for promoting anti-diabetic and anti-obesity effects, comprising herbal extract

The present invention relates to a composition for improving anti-diabetic and anti-obesity effects, including an extract extracted from any one selected from the group consisting of lonicera japonica (lonicerae flos), scutellaria baicalensis (scutellariae radix), and houttuynia cordata (houttuyniae herba). According to the present invention, it was confirmed that co-administration of the extract of the present invention and metformin, a representative anti-diabetic drug, increases an anti-diabetic effect and reduces side effects caused by metformin, and at the same time, exhibits an anti-obesity effect by suppressing fat accumulation.
Dongguk University Gyeongju Campus Industry- Academy Cooperation Foundation

Treating a bacterial skin infection with a whole, leech saliva extract

Methods are also provided for isolating and using a whole-saliva leech extract in the treatment of a bacterial skin infection. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° c.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech.
Biopep Solutions, Inc.

Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof

This invention concerns pyrroloquinoline derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, parkinson's disease, huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, irritable bowel syndrome.
Universite De Montpellier

Telemonitoring system !

Disclosed is a telemonitoring system and associated methods. A doctor creates a care plan for a patient with a chronic condition, such as diabetes.
Esvyda!, Inc.

Protein and protein conjugate for diabetes treatment, and applications thereof

The present invention relates to the field of biopharmaceuticals, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is glp-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a gip receptor binding polypeptide or an analogue thereof.
Adda Biotech Inc.

Cyclic polypeptides for the treatment of heart failure

Or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein x1, x3, x4, x7, x8, x9, x10, x11, x12 and x13 are defined herein. The polypeptides are agonist of the apj receptor.

Adjusting insulin delivery rates

A method may include displaying to a user an interface at which the user inputs a fear of hypoglycemia index (fhi), the fhi corresponding to an acceptable probability of a blood glucose level being below a threshold blood glucose level. The method may also include receiving blood glucose data for a person with diabetes (pwd).
Bigfoot Biomedical, Inc.

Soluble mediator

The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a subject..
The Walter And Eliza Hall Institute Of Medical Research

Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use

The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors.
Strongbridge Biopharma Plc

Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes and other diseases

Stem cell-based therapies can potentially reverse organ dysfunction and diseases but the removal of impaired tissue and reactivation of the program leading to organ regeneration pose major challenges. In mice, a four-day fasting mimicking diet (fmd) induces a step-wise expression of sox17 and pdx-1, resembling that observed during pancreatic development and followed by ngn3-driven generation of insulin-producing β-cells.
University Of Southern California

Cafestol for treating diabetes

A method is provided of treating, preventing or ameliorating type 2 diabetes and/or a clinical condition associated with type 2 diabetes, which method comprises administering an effective amount of cafestol or a derivative thereof including esters and salts thereof to a person in need thereof. Further provided are compositions comprising cafestol and at least one additional agent suitable for treating, preventing or ameliorating diabetes and/or a clinical condition associated with diabetes.
Region Midtjylland

Method for treating a neurovascular complication of diabetes mellitus

A method of preventing and/or treating a disease caused by diabetes complications includes administering to a patient in need thereof, an effective amount of thymoquinone or a pharmaceutically acceptable salt thereof, either singly or in combination with a pharmaceutically acceptable carrier, diluent or excipient. The disease can be at least one of retinopathy, nephropathy, neuropathy, and neurological disorder..
King Saud University

Apparatus, chronic disease monitoring

An apparatus, system, and method for monitoring a person suffering from a chronic medical condition predicts and assesses physiological changes which could affect the care of that subject. Examples of such chronic diseases include (but are not limited to) heart failure, chronic obstructive pulmonary disease, asthma, and diabetes.
Resmed Sensor Technologies Limited

Pig model for diabetes

The present invention relates to a transgenic pig comprising a mutated iapp gene and displaying a phenotype associated with diabetes. The invention also relates to a transgenic blastocyst, embryo, fetus, donor cell and/or cell nucleusderived from said transgenic pig.
Aarhus Universitet

Electronic phenotyping technique for diagnosing chronic kidney disease

An example method of diagnosing chronic kidney disease (ckd) includes obtaining an electronic medical record for a patient having medical data. The medical data includes an indication if the patient had been previously diagnosed with ckd, an indication if the patient had previously undergone a kidney transplant, an indication if the patient had previously undergone a renal dialysis procedure, an indication if the patient had previously been diagnosed with another type of kidney disease, one or more glomerular filtration rate (gfr) measurements associated with the patient, an indication if the patient has type 2 diabetes, and/or an indication if the patient has hypertension.
Icahn School Of Medicine At Mount Sinai

Insulinotropic peptide derivative with modified n-terminal charge

The present invention relates to an insulinotropic peptide derivative with a modified n-terminal charge and a pharmaceutical composition including the same. Specifically, the insulinotropic peptide derivative is characterized in that the n-terminal positive charge of the insulinotropic peptide is modified to a neutral or net negative charge at neutral ph.
Hanmi Pharm. Co., Ltd.

Chemical compounds and use thereof for improving muscular quality

Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity.
Universite Paris 6 Pierre Et Marie Curie

N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase

Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are n-alkylated d-galacto, d-gluco- or l-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“x”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards gcs, and/or an increased inhibitory potency towards gba2, and/or a decreased inhibitory potency towards gba1, relative to known deoxynojirimycin derivatives of the same (d-gluco, l-ido or d-galacto) configuration.
Universiteit Leiden

Device for attachment to a portable liquid injection device

The invention refers to a device for attachment to a portable liquid injection device, wherein said device is designed to enclose the drug reservoir of the injection device completely. Further, said device has at least two flat conductive electrodes enabling an electrical field to be applied across the entire volume of the drug reservoir of the injection device.
Valtronic Technologies (holding) Sa

Method of preventing and treating retinal microvasculature inflammation using c-met signaling pathway inhibition

The present invention provides methods for preventing retinal microvasculature inflammation in patients with diabetes who are highly susceptible to developing diabetic retinopathy and/or diabetic macular edema. The methods comprise inhibiting c-met signaling pathway by administering a c-met inhibitor alone or in combination with anti-vegf or steroid medications to diabetic patients.

Nutritional support health issues

A method of improving the outcome or recovery for depression, diabetes, cardiovascular disease, alzheimers progression, or breast cancer. This method consists of administering a food which includes transfer factor, lactic acid generating bacteria, and/or glucans in appropriate combinations and dosage levels.
Cortcontrol

Phospholipid-containing marine extracts for treatment of cardiovascular diseases

The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient.
Neptune Technologies & Bioressources, Inc.

Aromatic farnesyl compound and application thereof

Aromatic farnesyl compound and application of a pharmaceutical salt thereof as an inhibitor of α-glucosidase, dipeptidyl peptidase-4, aldose reductase, protein tyrosine phosphatase-1b or hmg-coa reductase, or use thereof in preparing medicine and functional healthcare products having a liver protective function and/or for treating and/or preventing type ii diabetes, diabetic retinopathy, diabetic foot disease, and hyperlipidemia.. .
Institute Of Microbiology, Chinese Academy Of Sciences

Specialized flour for nutrition meals for diabetes and preparation method and use thereof

Disclosed are specialized flour for nutrition meals for diabetes and a preparation method and use thereof. The flour is based on cereal meal as a basic material and is added to a defatted soybean vegetable protein powder and a soybean tissue isolated dietary fiber power, wherein in the dry flour base, the content of protein is 20-26 weight %, the content of the dietary fiber is 4-10 weight %, the content of carbohydrate is no more than 65 weight %, and the content of fat is no more than 4% of the weight.

System and decision support using lifestyle factors

Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions.
Dexcom, Inc.

System and decision support using lifestyle factors

Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions.
Dexcom, Inc.

Composition and using mir-302 precursors as drugs for treating alzheimer's diseases

This invention generally relates to a composition and method of using recombinant micrornas (mirna) and their hairpin-like precursors (pre-mirna) as therapeutic drugs for treating alzheimer's diseases (ad). More specifically, the present invention relates to the use of man-made mirna mir-302 precursors (pre-mir-302) for ad therapy in humans.
Mello Biotechnology, Inc.

Compositions and methods for measuring nmu and for treatment using anti-nmu agents

The inventors have produced two high specificity and high affinity monoclonal antibodies that bind to human neuromedin u (nmu). Methods and compositions are provided for treating an individual in need thereof (e.g., an individual who is obese and/or has diabetes) by administering an anti-nmu/nmur agent (e.g., an anti-nmu antibody).
The Board Of Trustees Of The Leland Stanford Junior University

Humanized antibodies specific for hsp65-derived peptide-6, methods and uses thereof

The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by seq id no. 15, that is an hsp65 derived peptide.
Protab Ltd.

Novel 3-amino-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives

Wherein a, b, r1, r2, r3, r4, r5, r6, r7, r8, r9 and r10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, alzheimer's disease and dermatological disase pression, virus diseases, inflammatory disorders, or diseases in which the liver is a target organ..

Amlexanox analogs

Provided herein are amlexanox analogs and methods for the treatment and/or prevention of diabetes, impaired insulin signaling, obesity, or other related diseases and conditions therewith.. .
The Regents Of The University Of Michigan

[7,6]-fused bicyclic antidiabetic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

The present invention provides compounds of formula (i) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are gpr40 g protein-coupled receptor modulators which may be used as medicaments..
Bristol-meyers Squibb Company

Antidiabetic bicyclic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Antidiabetic bicyclic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders

Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of s1p1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type i diabetes, acne, microbial infections or diseases and viral infections or diseases.. .

Swallowable capsule and stimulating incretin production within the intestinal tract

Embodiments of the invention provide apparatus and methods for stimulating l cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating l-cells to secrete incretins to stimulate or otherwise modulate the production of insulin.
Incube Labs, Llc

Dry powder inhaler

A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation..
Mannkind Corporation

System and decision support using lifestyle factors

Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions.
Dexcom, Inc.

Functionalized exendin-4 derivatives

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.. .
Sanofi

Use of dehydroeburicoic acid from antrodia camphorata in the treatment or prevention of diabetes and hyperlipidemia

The present invention provides a method for treating type 1 diabetes, hyperlipidemia or hepatic lipid accumulation by using dehydroeburicoic acid, as well as a method for decreasing levels of blood glucose, plasma total cholesterol, and triglyceride, and increasing insulin levels; and a method for decreasing hepatic balloon degeneration; and increasing expression levels of membrane glut4 and phospho-akt in myotubes; and enhancing expression levels of membrane glucose transporter 4 (glut4) in skeletal muscle, and phospho-ampk in both skeletal muscle and liver tissue using dehydroeburicoic acid.. .

Phenoxy acetic acids and phenyl propionic acids as ppar delta agonists

Phenoxy acetic acids and phenyl propionic acids and their use in treating type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of pparδ and may be useful for treating conditions mediated by the same..
Vtv Therapeutics Llc

Aldose reductase inhibitors and uses thereof

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like..
The Trustees Of Columbia University In The City Of New York

Aldose reductase inhibitors and uses thereof

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like..
The Trustees Of Columbia University In The City Of New York

Compositions for treating or preventing obesity and insulin resistance disorders

Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively..
The General Hospital Corporation D/b/a Massachusetts General Hospital

Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor

Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.. .
Merch Sharp & Dohme Corp.

Glucagon antagonists

Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including type i and ii diabetes, insulin resistance and hyperglycemia.
Ligand Pharmaceuticals, Inc.

Screening and monitoring the progression of type 2 diabetes by the molecular identification of human gut flora using fta as a faecal collection device

Disclosed is a method for detecting and quantifying gut flora derived from human faeces, comprising acquiring a solid support containing human faeces; optionally amplifying nucleic acid from the human faeces; and detecting and quantifying the presence of gut flora of interest. Also disclsoed is a method for assessing whether a person has type-2 diabetes as well as a kit for detecting and quantifying gut flora from human faeces, comprising a solid support for collecting human faeces; and primer pairs for amplifying 16s rrna sequence from bacteria of interest..
Ge Healthcare Uk Limited

High-purity galactooligosaccharide compositions, preparations, and applications thereof

Provided is a method of preparing a high-purity galactooligosaccharide composition by fermentation of a low-purity galactooligosaccharide mixture with a yeast strain, kluyveromyces lactis atcc 8585. The high-purity galactooligosaccharide composition includes at least 99% of galactooligosaccharides selected from the group consisting of galactotriose, galactotetrose, galactooligosaccharides with five or more sugar units, and combinations thereof and lower than 1% of monosaccharides and disaccharides.
King-prebiotics Biotechnology (tw) Co., Ltd.

[5,6]-fused bicyclic antidiabetic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Deutero-phenformin derivatives

The present disclosure is directed to novel phenformin derivatives, and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof. This disclosure also provides compositions and the use of such compositions in method of treating cancer, diabetes, or polycystic ovarian syndrome..
Enlibrium Inc

A peptide therapy to counteract insulin resistance and type 2 diabetes

Compositions comprising an antagonist of pancreastatin are provided. The beneficial use of the compositions for treating insulin resistance, diabetes, especially type ii diabetes, inflammation, obesity, non-alcoholic fatty liver disease, atherosclerosis and cardiovascular diseases is described as well..
Indian Institute Of Technology Madras

Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes

In another aspect, the present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject. The present invention is also directed to pharmaceutical compositions that include the above compounds and a pharmaceutically acceptable carrier..

Socs1-derived peptide for use in chronic complications of diabetes

The present invention relates to a socs1-derived peptide for use in chronic complications of diabetes, particularly ocular, renal, nerve and vascular complications, as well as compositions containing same and isolated polynucleotides encoding same. The present invention also relates to the socs1-derived peptide for topical use in the treatment and/or prevention of neurodegenerative diseases of the retina, particularly in the early stages of diabetic retinopathy and other diseases of the retina in which neurodegeneration plays an essential role..
Universidad Autónoma De Madrid

Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients

The present invention relates to a food composition, and to a pharmaceutical composition, which exhibit anti-obesity effects by means of a thermogenesis produced by an activity of a ucp of fat cells, which exhibit anti-diabetes effects by means of an improved insulin resistance, increase muscle mass, and improve capacity for exercise. More particularly, the present invention relates to a novel use of a composition containing extracts of piper retrofractum, and to the food composition or pharmaceutical composition which exhibit anti-obesity effects by means of decreased body weight and body fat, exhibit anti-diabetes effects by means of ameliorated insulin resistance through the reduction of blood glucose and blood insulin, increase muscle mass by increasing an energy source being supplied to the muscles, and improve the capacity for exercise including increased endurance..
Industry-academic Cooperation Foundation, Yonsei University

A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation

This invention provides combinations of kynurenine and antigen presenting cells (apc) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of type 1 diabetes (t1d) or alopecia areata (aa). Uses of kynurenine and antigen presenting cells (apc) as an immune modulator for the treatment of t1d or aa are also provided..
The University Of British Columbia

Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

The present invention concerns the use of compounds for preventing and/or treating diabetes, for modulating glucose, insulin, and/or triglyceride levels; for reducing blood glucose level; for maintaining or increasing insulin level; for increasing insulin secretion; increasing insulin sensitivity; or decreasing insulin resistance in a subject. These novel uses have been found for compounds represented by formula i and pharmaceutically acceptable salts.
Prometic Pharma Smt Limited

Biguanide compositions and methods of treating metabolic disorders

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention.
Elcelyx Therapeutics, Inc.

Biochemical markers for use in determining risk of diabetes

A method for predicting risk of gestational diabetes mellitus (gdm) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of amylin, 17β-estradiol, and lipocalin-2, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing gdm.. .
Wallac Oy

Goodpasture antigen binding protein detection and inhibition and its use in diabetes

Disclosed herein are methods for treating type 2 diabetes, limiting development of type 2 diabetes, and treating a pre-diabetic state by administering to a subject in need thereof a gpbp inhibitor. Also disclosed herein are methods for diagnosing a pre-diabetic state and for diagnosing a propensity to develop type 2 diabetes by determining an amount of gpbp in a sample from a subject and comparing to control..
Fibrostatin, S.l.

Method of designing a peptide and/or peptide derivative for modulating gamma-c-cytokine activity

The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Preparation and use of crystalline beta-d-nicotinamide riboside

Provided herein are crystalline beta-d-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof.
Glaxosmithkline Intellectual Property (no.2) Limited

Adjusting insulin delivery rates

A method may include delivering insulin, using an insulin pump and a controller, over a first diurnal time period based on a baseline basal insulin rate stored in memory. The controller may receive blood glucose data to control delivery of insulin via the insulin pump in amounts variable from the baseline basal insulin rate to control blood glucose levels for a person with diabetes (pwd).
Bigfoot Biomedical, Inc.

Diabetes management system

A variety of location-based and/or proximity-based features related to diabetes management systems can be used to improve maintenance compliance and/or to provide important information to pwd designated assistance entities (e.g., family, friends, givers, hcps, emergency medicine providers) under certain conditions. In some cases, a user's location can be tracked or determined to trigger and/or time alerts about upcoming maintenance tasks in a way that will increase the likelihood that the pwd will immediately perform the designated maintenance task.
Bigfoot Biomedical, Inc.

Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof

Compositions and preparation method thereof, said compositions comprise an extract from a mixture comprising cyclocarya paliurus leaves and one or more herbs selected from the group consisting of mori cortex, dendrobii caulis and citri reticulatae pericarpium, said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia.. .
Infinitus (china) Company Ltd

Small molecule inhibitors of stat3 with anti-tumor activity

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s3i-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.
University Of Central Florida Research Foundation.

Biguanide compositions and methods of treating metabolic disorders

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention.
Elcelyx Therapeutics, Inc.

User interface for diabetes management system

A diabetes management system including a pump for dispensing a medicant and a control device for controlling the pump includes a user interface for controlling functions of the pump and providing information related to operation of the pump and other information. The user interface can display blood glucose information and insulin dosing data such that a user can appropriately act on the information and/or gain confidence that the diabetes management system is operating appropriately to manage the disease.
Bigfoot Biomedical, Inc.

Methods of treating diabetes and compositions capable of same

A composition of matter is disclosed which comprises isolated oligomers of human islet amyloid polypeptide (iapp). Antibodies recognizing same are also disclosed.
Ramot At Tel-aviv University Ltd.

Agonists of the apelin receptor and methods of use thereof

Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
Sanford-burnham Medical Research Institute

Ultrashort peptides as exogenous second harmonic probes for bioimaging applications

Various aspects of the present invention relate to a peptide based biomaterial for visualization by shg microscopy. In particular the invention relates to the use of short peptides as a non-linear optical (nlo) material for second harmonic generation (shg) microscopy.
Agency For Science, Technology And Research

Composition for treating diabetes mellitus comprising insulin and a glp-1/ glucagon dual agonist

A composition for preventing or treating diabetes mellitus includes insulin and a glp-1/glucagon dual agonist. The composition can inhibit the weight gain and reduce the danger of hypoglycemia due to the administration of insulin, lower the administration dose and greatly improve the compliance of drugs through a combined administration of a long-acting insulin conjugate and a long-acting glp-1/glucagon dual agonist conjugate.
Hanmi Pharm. Co., Ltd.

Enhancement of glucose-stimulated insulin secretion by cells through induction of cellular senescence

Methods for increasing glucose induced insulin secretion in an insulin secreting cell by inducing senescence in the cell are provided. Further, methods for treating diabetes, by providing cells with increased glucose induced insulin secretion to a subject, as well as a population of modified insulin secreting cells are provided..
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

Compositions and methods of treating diabetic retinopathy

A method of treating diabetic retinopathy in a subject in need thereof includes administering to the subject a therapeutically effective amount of one or more agents that act as a trap of reactive aldehydes and/or inhibit diabetes-induced superoxide generation and capillary degeneration regulated by gpcr signaling pathways.. .
Case Western Reserve University

Tgr5 agonist complexes for treating diabetes and cancer

Provided herein are complexes of metformin or metformin analogues and a tgr5 ligand that are useful in treating diseases including diabetes, cardiovascular disease, and cancer.. .
City Of Hope

Heterocyclic gsk-3 allosteric modulators

The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (gsk-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein gsk-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes..
Consejo Superior De Investigaciones Cientificas (csic)

Ex vivo browning of adipose tissue therapy for reversal of obesity and type ii diabetes

Provided are methods, apparatus, pharmaceutical compositions, and kits for treatment of a metabolic condition, including obesity and type 2 diabetes, by administration to a subject of a therapeutically effective amount of a cell or tissue preparation such as brown adipose microtissues or brown adipose tissue directly converted from white adipose tissue. Modified approaches to creating brown adipose tissue involve differentiation of explanted white adipose tissue and direct browning of white adipose tissue in a bioreactor rather than isolation and expansion of adipose stems cells or endothelial cells and formation and differentiation of 3d cell aggregates..
The Trustees Of Columbia University In The City Of New York

Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease

An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human tnf. Such binding disrupts assembly of the monomer into bioactive trimeric human stnf.
Thymon, Llc

Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases

The specification provides compositions comprising chimeric proteins comprising aat conjugated to an fc region of an immunoglobulin. Methods for treating autoimmune disease, e.g., diabetes, e.g., type 1 and type 2 diabetes, are also provided..
Beth Israel Deaconess Medical Center, Inc.

Novel glucagon analogues

The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

Pyridine derivative

Provided is a pyridine derivative represented by formula (i), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with urat1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and lesch-nyhan syndrome.. .
Teijin Pharma Limited

Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient

The present disclosure relates to an exendin-4 analogue pegylated with polyethylene glycol or a derivative thereof, a preparation method, and a pharmaceutical composition for prevention or treatment of diabetes containing the same as an active ingredient. According to the present invention, the yield of an exendin-4 analogue can be increased via the selective pegylation by using exendin-4 in which a cysteine is introduced into #40 site of the c-terminal, and treatment effect of medications can be increased, so that the exendin-analogue can be usefully applied as a composition for prevention or treatment of diseases caused by insulin hypersecretion..
Theraly Pharmaceuticals Inc.

Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity and metabolic and immunological alterations

The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products.
Consejo Superior De Investigaciones Cientificas

Transgenic pig islets and uses thereof for treating diabetes

The present invention relates to an isolated transgenic pig beta cell wherein the pkc and the pka pathway are constitutively activated; to a transgenic pig islet comprising said transgenic pig beta cell; and to a transgenic pig comprising said transgenic pig beta cell or said transgenic pig islet. Another object of the invention is a device comprising a transgenic pig beta cell or a transgenic pig islet of the invention.
UniversitÉ Catholique De Louvain

Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy

Methods for treatment of insulin resistance and type ii diabetes by administration of inhibitors of the pki pathway are provided. In some aspects, inhibitors of the pki pathway, such as inhibitors of pikb, hif1 and/or mtor, can be used to treat subject having insulin resistance who are refractory to glp1 agonist therapy..
Research Development Foundation

Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions

The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, visceral obesity and abdominal obesity, and metabolic syndrome.. .
Boehringer Ingelheim International Gmbh

Solid oral formulation of fenretinide

Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited to cancers, conditions associated with a lipid imbalance, cystic fibrosis, osteoporosis, conditions associated with inflammation or opportunistic infections, and other diseases such as diabetes, obesity, dry-form age-related macular degeneration..
Laurent Pharmaceuticals

Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction

The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of type ii diabetes mellitus, the metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of β-cell compensation..
Merck Patent Gmbh

Composition and management of diabetes or pre-diabetes

Wherein the drink exhibits shear banding when subject to the shear banding test herein described.. .



Diabetes topics:
  • Immune Disorder
  • Autoimmune
  • Immune Disease
  • Immune Diseases
  • Autoimmune Disorder
  • Type 1 Diabetes
  • Autoimmune Disorders
  • Vascular Diseases
  • Antimicrobial
  • Cardiovascular
  • Inflammatory Disease
  • Antimicrobial Agent
  • Stem Cells
  • Human Embryonic Stem Cell
  • Embryonic Stem Cell


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Diabetes for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Diabetes with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.3573

    file did exist - 12632

    0 - 1 - 261